Quote | Nuvation Bio Inc. Class A (NYSE:NUVB)
Last: | $2.62 |
---|---|
Change Percent: | -1.5% |
Open: | $2.64 |
Close: | $2.66 |
High: | $2.65 |
Low: | $2.525 |
Volume: | 318,675 |
Last Trade Date Time: | 04/25/2024 03:00:00 am |
News | Nuvation Bio Inc. Class A (NYSE:NUVB)
Nuvation Bio Inc. (NYSE: NUVB), a late-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced that updated data from the Phase 2 TRUST-I clinical study (NCT04395677) evaluating ta...
Transforms Nuvation Bio into late-stage global oncology company with potential to become a commercial organization by the end of 2025 Shareholders of Nuvation Bio and AnHeart Therapeutics immediately prior to close now own approximately 67% and 33%, respectively, of Nuvation Bio on a full...
Message Board Posts | Nuvation Bio Inc. Class A (NYSE:NUVB)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Nuvation Bio Inc. Class A Company Name:
NUVB Stock Symbol:
NYSE Market:
Nuvation Bio Inc. (NYSE: NUVB), a late-stage, global biopharmaceutical company tackling some of the greatest unmet needs in oncology by developing differentiated and novel therapeutic candidates, today announced that updated data from the Phase 2 TRUST-I clinical study (NCT04395677) evaluating ta...
U.S. stocks were mixed, with the Nasdaq Composite falling over 100 points on Friday. Shares of Fifth Third Bancorp (NASDAQ:FITB) rose during Friday...
Transforms Nuvation Bio into late-stage global oncology company with potential to become a commercial organization by the end of 2025 Shareholders of Nuvation Bio and AnHeart Therapeutics immediately prior to close now own approximately 67% and 33%, respectively, of Nuvation Bio on a full...